Of all the metabolic variables that tesamorelin researchers log alongside visceral fat measurements, HbA1c is the one that generates the most questions — and the most misread results. The mechanism is straightforward: tesamorelin stimulates the pituitary to release growth hormone in pulses that more closely resemble the physiological pattern, and GH itself is a well-characterised counter-regulatory hormone. It suppresses glucose uptake in skeletal muscle, drives hepatic gluconeogenesis, and mobilises free fatty acids. None of that is pathological at physiological GH concentrations — but in a research context where investigators are tracking multiple biomarkers, it matters enormously that they are watching the right glucose signals, on the right timeline, with the right tools.
This guide is for research teams in Dubai, Abu Dhabi and across the UAE who want a practical, evidence-anchored glucose monitoring framework to layer onto a tesamorelin protocol. REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin 5mg and 10mg vials across all 7 emirates — with tesamorelin in stock UAE available for same-day Dubai dispatch or tesamorelin Dubai 24h delivery to every other emirate.
To understand why HbA1c monitoring belongs in any serious tesamorelin research protocol, start with growth hormone's metabolic role. GH acts via the GH receptor in the liver and peripheral tissue, triggering JAK2-STAT5 signalling that increases IGF-1 production and simultaneously activates lipolytic pathways. The lipolytic cascade releases free fatty acids (FFAs) into circulation, which compete with glucose for oxidation in skeletal muscle (the Randle cycle). The net effect is reduced peripheral glucose disposal — an insulin-antagonistic state.
In the Falutz et al. 2007 NEJM trial — the landmark 412-subject lipodystrophy study that used tesamorelin at a 2 mg/day research-context dose — investigators documented a ~50% rise in IGF-1 and a 15-18% reduction in visceral adipose tissue versus placebo. Metabolic safety data were tracked across the cohort, and the study team included fasting glucose and insulin resistance markers as secondary endpoints precisely because the GH axis was being engaged. The 2010 26-week extension (also Falutz, NEJM) continued those assessments through the longer observation window.
Stanley and colleagues at Massachusetts General Hospital, working on HIV-associated NAFLD (Stanley 2014, JAMA; Stanley 2019, Lancet HIV), saw comparable IGF-1 responses and 32% reductions in liver fat at 12 months — again with metabolic monitoring embedded in the protocol design. The message across all four of these reference studies is consistent: glucose tracking is not optional in tesamorelin research. It is a core data stream.
HbA1c measures the percentage of haemoglobin glycated over the preceding 90 days and provides a smoothed average of glycaemic exposure that momentary fasting glucose tests cannot. In tesamorelin research, HbA1c serves as the integrated signal that captures whether GH-driven glucose shifts are cumulative and sustained versus transient and self-correcting.
The clinical research using tesamorelin — the Falutz and Stanley trials cited above — enrolled subjects over 26-week and 12-month windows. A 90-day HbA1c draw therefore sits neatly at or before the midpoint of a standard research protocol, capturing the glucose environment during the period of maximum GH stimulation.
| Study | N | Duration | Key Metabolic Finding | Glucose Monitoring Approach |
|---|---|---|---|---|
| Falutz et al. 2007 (NEJM) | 412 | 26 weeks | VAT -15-18%; IGF-1 +~50%; metabolic safety tracked | Fasting glucose, insulin resistance markers (HOMA-IR) |
| Falutz et al. 2010 (NEJM extension) | subset | 52 weeks | Sustained VAT reduction; long-run metabolic safety data collected | Serial glucose and lipid panels throughout extension |
| Stanley et al. 2014 (JAMA) | HIV-NAFLD cohort | 12 months | Liver fat -32% vs placebo; IGF-1 normalised | HbA1c and fasting glucose at baseline, mid-point, end-point |
| Stanley et al. 2019 (Lancet HIV) | randomised, double-blind | 12 months | Maintained liver fat reduction; metabolic markers followed | Serial metabolic panels per protocol |
The practical implication: research teams should design their glucose monitoring schedule around these same timepoints — not improvising them mid-protocol when an anomalous reading appears.
Investigators sometimes conflate two different glucose signals. A glucose spike is a post-prandial excursion driven by carbohydrate load — it is transient and largely unrelated to GH dynamics. Glucose drift is the slow, persistent elevation in fasting glucose that can occur when GH chronically suppresses peripheral insulin sensitivity. HbA1c primarily reflects glucose drift, not individual spikes. A CGM sensor, by contrast, can detect both — which is why the most rigorous tesamorelin research protocols use both tools in combination.
Continuous glucose monitoring (CGM) sensors — worn interstitially on the upper arm or abdomen — provide a glucose reading every 1-5 minutes for 14-day sensor windows. In the context of tesamorelin research, CGM does something an HbA1c lab draw cannot: it shows when glucose elevates, not just by how much on average. GH peaks naturally in the early morning hours (the GH pulse pattern that tesamorelin amplifies), so fasting glucose elevation due to GH counter-regulation tends to manifest as elevated early-morning interstitial glucose — the classic "dawn phenomenon" amplified by GH axis stimulation.
Both have a role. Finger-stick fasting glucose is inexpensive, produces a discrete number that maps cleanly to reference ranges, and is the format used in the Falutz and Stanley trial protocols. CGM provides continuous granularity but requires calibration, has a 15-20 minute lag behind blood glucose, and generates a data volume that needs aggregating before it is meaningful. For a research protocol monitoring a 12-24-week tesamorelin window, the practical hierarchy is:
| CGM Metric | What It Measures | Research Relevance in Tesamorelin Context |
|---|---|---|
| Fasting interstitial glucose (6-9 AM average) | Overnight and dawn-phase glucose | Primary signal for GH counter-regulatory effect — elevated early-morning glucose is the earliest CGM indicator |
| Time in Range (TIR, 70-180 mg/dL) | % of 24-hour period within normal glycaemic band | Tracks overall glycaemic stability; a declining TIR over the protocol window flags sustained glucose drift |
| Mean Amplitude of Glycaemic Excursions (MAGE) | Average peak-to-trough swing in glucose | Detects post-prandial volatility, which can increase if insulin sensitivity declines |
| Time Above Range (TAR, >180 mg/dL) | % of 24-hour period above upper normal limit | Flags persistent hyperglycaemic exposure; relevant if fasting glucose is already elevated at baseline |
| Glucose Management Indicator (GMI) | Estimated HbA1c derived from CGM average | Cross-check against lab HbA1c; discrepancies (>0.5%) prompt review of CGM calibration or haemoglobin variant status |
A tesamorelin research protocol using 1-2 mg/day — the dosing range referenced in the Falutz and Stanley investigations, and the research-context dose for REVIVE LAB UAE's 5mg and 10mg vials — runs long enough that glucose monitoring needs deliberate scheduling, not ad hoc testing. The following framework mirrors the assessment cadence used in the pivotal trials.
Before commencing any tesamorelin research protocol, investigators establish the subject's glycaemic baseline across three parameters: a fasting venous glucose, an HbA1c, and a fasting insulin level for HOMA-IR calculation. This baseline is the reference against which all subsequent readings are interpreted. A baseline HbA1c above 6.0% warrants heightened monitoring frequency throughout the protocol — more frequent fasting glucose draws rather than waiting for the 12-week HbA1c assessment.
Week 4 represents the period when GH pulsatility has stabilised at its elevated tesamorelin-stimulated level and the acute lipolytic effects are in full swing. A fasting glucose draw at this point catches any early glucose drift before it compounds. If a CGM sensor is being used, this is the optimal window to place it — the 14 days covering weeks 4-6 give the most informative continuous picture of GH-driven glucose dynamics.
The week 12 HbA1c is the most clinically meaningful single lab draw in a tesamorelin research protocol. It reflects the glycaemic average from approximately weeks 4 through 12 — the period of full GH stimulation. The Falutz 2007 and Stanley 2014 trials both drew metabolic assessments at this approximate midpoint. A fasting glucose and fasting insulin should accompany the HbA1c to allow updated HOMA-IR calculation.
The Falutz 2010 extension ran to 52 weeks total; the standard research benchmark is a 26-week primary endpoint. A final HbA1c, fasting glucose, and insulin panel closes the metabolic dataset and establishes whether any glucose drift observed at week 12 was progressive, plateaued, or resolved during continued protocol.
| Timepoint | HbA1c | Fasting Glucose | Fasting Insulin / HOMA-IR | CGM Sensor |
|---|---|---|---|---|
| Week 0 (Baseline) | Yes | Yes | Yes | Optional 14-day pre-protocol baseline |
| Week 4 | No | Yes | Optional | Recommended — 14-day active-phase sensor |
| Week 12 | Yes | Yes | Yes | Optional second sensor week 12-14 |
| Week 24-26 | Yes | Yes | Yes | Optional end-of-protocol sensor |
Research teams unfamiliar with GH axis pharmacology sometimes alarm unnecessarily at a modest fasting glucose rise during a tesamorelin protocol, or conversely miss a drift that warrants attention. The following framework helps categorise observations:
The Stanley 2019 Lancet HIV 12-month trial provides the longest-duration metabolic safety dataset for tesamorelin at research-context dosing. The metabolic safety profile across that 12-month window informed the ongoing use of tesamorelin as the reference GHRH analog in metabolic research — including the liver fat and visceral adipose tissue work that REVIVE LAB UAE's research clients in Dubai and Abu Dhabi are most commonly investigating.
REVIVE LAB UAE supplies tesamorelin in two vial sizes for research use. The reconstitution options below map to the 1-2 mg/day dosing referenced in the Falutz and Stanley protocols — the most studied research-context dose range for this GHRH analog.
| Vial Size | BAC Water Added | Resulting Concentration | Volume for 1 mg Research Dose | Volume for 2 mg Research Dose |
|---|---|---|---|---|
| Tesamorelin 5 mg | 1 mL | 5 mg/mL | 0.2 mL (20 IU on insulin syringe) | 0.4 mL (40 IU) |
| Tesamorelin 5 mg | 2 mL | 2.5 mg/mL | 0.4 mL (40 IU) | 0.8 mL (80 IU) |
| Tesamorelin 10 mg | 2 mL | 5 mg/mL | 0.2 mL (20 IU) | 0.4 mL (40 IU) |
| Tesamorelin 10 mg | 4 mL | 2.5 mg/mL | 0.4 mL (40 IU) | 0.8 mL (80 IU) |
All REVIVE LAB UAE tesamorelin vials are dispatched lyophilized (freeze-dried) in cold-chain validated insulation. Reconstitute slowly by adding bacteriostatic water down the inside wall of the vial — never inject directly onto the peptide cake. Store reconstituted vials at 2-8°C and use within 14 days. Lyophilized vials may be stored at 2-8°C until use. Glucose monitoring within a research protocol should be timed to the protocol calendar, not to reconstitution date.
For researchers running active monitoring protocols in Dubai, Abu Dhabi or any emirate, supply continuity matters. A gap in tesamorelin availability mid-protocol disrupts both the GH stimulation window and the glucose monitoring timeline — because the glucose readings only make sense relative to ongoing peptide administration. This is why having a UAE-based supplier with tesamorelin in stock UAE is a protocol-design consideration, not just a convenience.
REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates. Peptides UAE researchers can buy tesamorelin UAE with same-day delivery in Dubai and next-day delivery everywhere else. Cash on delivery Dubai is supported, as is next-day cash on delivery to Abu Dhabi, Sharjah, RAK and Fujairah.
| Emirate / City | Delivery Window | Cash on Delivery | Cold-Chain Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, DIFC, Downtown, JVC, Palm, Jumeirah) | Same-day, 4-8 hours | Yes | Yes — insulated cold pack |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem Island) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain / Al Ain | Next-day, 18-24 hours | Yes | Yes |
Yes, it can. Tesamorelin is a GHRH analog that raises endogenous GH pulsatility. Growth hormone is a counter-regulatory hormone that promotes hepatic gluconeogenesis and reduces peripheral glucose uptake — a combination that can elevate fasting glucose and, over a 12-week research window, shift HbA1c. The Falutz et al. 2007 NEJM trial (412 subjects) and the Stanley et al. 2014 JAMA and 2019 Lancet HIV studies all embedded glucose and metabolic safety monitoring as secondary endpoints. Research investigators standardly track fasting glucose at baseline, week 4, week 12, and end-of-study, with HbA1c drawn at baseline and 12-week intervals — the same cadence used in the pivotal trial designs.
Yes. REVIVE LAB UAE stocks tesamorelin 5mg and 10mg vials with HPLC-verified purity and lot-COA documentation. Orders placed before the daily cut-off receive tesamorelin same day Dubai delivery — covering Dubai Marina, JBR, Business Bay, DIFC, Downtown, JVC, Palm Jumeirah and Jumeirah — and tesamorelin Dubai 24h delivery to Abu Dhabi, Sharjah, RAK, Fujairah and all other emirates. Cash on delivery Dubai is available. All vials are dispatched cold-chain in insulated packaging to preserve the 2-8°C window.
Research teams running CGM alongside tesamorelin protocols typically focus on four metrics: (1) fasting interstitial glucose in the 6-9 AM window, which captures GH-driven overnight glucose — the earliest CGM signal; (2) Time in Range (TIR, 70-180 mg/dL) as an overall glycaemic stability indicator that integrates all glucose excursions; (3) Mean Amplitude of Glycaemic Excursions (MAGE) to detect post-meal volatility that may reflect reduced insulin sensitivity; and (4) HbA1c as the 90-day integrated marker drawn at baseline and week 12. Most rigorous protocols pair CGM for granular daily rhythm data with a static HbA1c lab draw for the long-run average — neither replaces the other.